Skip to main content

Growing advancement in cancer therapies to foster solid tumors treatment market growth

 


Market Overview:

 

A solid tumor can characterized by growth of abnormal mass or lump of tissues without liquid or cysts. It is classified into malignant tumor (cancerous) and the benign tumor (non-cancerous). Additionally, based on the cell type, tumors can be classified as sarcomas, carcinomas, and lymphomas.

Competitive Landscape:

Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc., Johnson & Johnson Company, Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline Plc., Sanofi, and Baxter International Incorporated

Key Market Drivers:

Growing popularity of biosimilars therapies is driving growth of the solid tumors treatment market. Moreover, rising prevalence of solid tumors is fueling market growth. According to the Centers for Disease Control and Prevention, in the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported and 146 people died of cancer.

Growing merger &acquisition in the market of cancer therapies by key players is again contributing to market growth. For instance, in July 2022, Takeda announced that it has acquire Adaptate Biotherapeutics to develop novel Gamma Delta (γδ) T Cell Engager therapies targeting solid tumors.

Covid-19 Impact Analysis

The COVID-19 pandemic crisis has had significant impact on the practice of tumor treatment. There was disruption in supply of raw materials used for production of solid tumor drug due to lockdown and social distancing norms.

Key Takeaways:

1.      The solid tumors treatment market is expected to exhibit a CAGR of XX % over the forecast owing to the growing prevalence of solid tumors and increasing popularity of biosimilar. According to the IQVIA, the three most recently launched biosimilars in 2019 have achieved significant uptake within their first year: bevacizumab (42%), trastuzumab (38%), and rituximab (20%).

2.       North America is expected to gain significant growth over the forecast period owing to the presence of well-established healthcare sector.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Virology Testing Market Detailed In New Research Report 2023

  Virology testing consist of diagnostic methods that help in early detection of the disease such as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other viral associated disease. Virology testing examines for detection of viral antigens, nucleic acids, and antibodies in the given sample in order to confirm the presence of particular viral infection. There are more than 100 viral diseases identified. Virology Testing Market- Market Dynamics Virology testing market is projected to witness significant growth during forecast period with rising prevalence of virus originated diseases such as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections, severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc. across world. Early and fast diagnosis of virus infection is very essential to start treatment course. According to the World Health Organization (WHO), January 2018 factsheet, all types of influenza in combination causes annual...
Post a Comment
Read more

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering ...
Post a Comment
Read more

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....
Post a Comment
Read more